iBio (NASDAQ:IBIO), an AI-driven pioneer in antibody discovery and development, announced on April 8, 2026, that it has received the necessary regulatory clearances to begin its Phase 1 clinical trial of IBIO-600, a novel candidate for the treatment of obesity.
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda).
Osisko Gold Royalties(NYSE:OR) reported record-breaking preliminary financial results for the first quarter of 2026 on April 8, bolstered by strong production across its core royalty portfolio and high precious metal prices.
Bausch + Lomb (NYSE:BLCO), a leader in eye health, announced on April 8, 2026, that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Bi-Blade+ dual-port vitrectomy cutter and an advanced Adaptive Fluidics update for the Stellaris Elite® Vision Enhancement System.
United Therapeutics (NASDAQ:UTHR), a leader in regenerative medicine and organ manufacturing, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational miroliverELAP®.
RPM International (NYSE:RPM) reported record financial results for its fiscal 2026 third quarter ended February 28, 2026, characterized by robust top-line growth and a significant expansion in operating margins across its global specialty coatings and building materials portfolio.
The Mosaic Company (NYSE:MOS) announced a significant restructuring of its Brazilian operations on April 8, 2026, confirming plans to idle and demobilize its Araxá Mining and Chemical Complex and halt related mining at Patrocínio.
Cango (NYSE:CANG), a global Bitcoin miner and energy infrastructure developer, announced its March 2026 operational update on April 8, detailing a strategic pivot toward a lean-production model that prioritizes cash margins over aggressive scale.
Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.
AtaiBeckley (NASDAQ:ATAI), a clinical-stage biopharmaceutical company developing next-generation mental health treatments, reported on April 8, 2026, peer-reviewed Phase 2a results demonstrating that a single intranasal dose of BPL-003 achieved rapid and sustained clinical benefits in patients with Treatment-Resistant Depression (TRD).
Pony.ai (NASDAQ:PONY), a global leader in autonomous driving technology, reached a historic milestone on April 8, 2026, with the launch of Europe’s first commercial robotaxi service in Zagreb, Croatia.
ECARX Holdings (NASDAQ:ECX), a global leader in automotive intelligence technology, announced on April 8, 2026, that its Board of Directors has approved a preliminary plan to pursue the acquisition of a minority interest and specific intellectual property assets related to FlyMe OS.
